Infantile Hepatic Hemangioendothelioma: An Uncommon Cause of Persistent Pulmonary Hypertension in a Newborn Infant

Trassanee Chatmethakul, MD1  Ramachandra Bhat, MD1  Maryam Alkaabi, MD1  Abdul Siddiqui, MD1  Keith Peevy, MD1  Michael Zayek, MD1

1 Department of Pediatrics, University of South Alabama, Mobile, Alabama

Abstract

Keywords

- infantile hepatic hemangioendothelioma
- persistent pulmonary hypertension of the newborn
- steroid
- propranolol

Multifocal and diffuse infantile hepatic hemangioendotheliomas commonly present with signs of high-output congestive heart failure. In addition, prolonged persistent pulmonary overcirculation eventually leads to the development of pulmonary hypertension at a later age. We report a 2-day old, full-term infant with multifocal, large infantile hepatic hemangioendothelioma, who presented with an early onset of pulmonary hypertension, managed successfully with supportive care and systemic therapy directed toward the involution of infantile hepatic hemangioendothelioma.

Case Report

A healthy appearing 39-week African-American male infant was born to a 35-year-old G4P3 (Gravida 4 and Para 3) mother with a prenatal history significant for chronic hypertension treated with methyldopa, and an abnormal triple screen with a normal karyotype on amniocentesis. He was born by an uncomplicated labor and delivery, with unremarkable physical findings, normal vital signs, and an uneventful clinical course during the first postnatal day. On the second postnatal day, an echocardiogram was performed secondary to a newly developed loud, holosystolic murmur at the left lower sternal border. It revealed a normally structured heart with maximum tricuspid regurgitation jet velocity of 4.4 m/s (estimated right ventricular systolic pressure of 77 mm Hg) and dilated right atrium and right ventricle, indicative of PPHN (→ Fig. 1). As he was clinically asymptomatic with normal pre- and postductal oxygen saturation (SpO2) and normal four extremities blood pressures, his care was continued in the newborn nursery. At
72 hours of age, he was transferred to the neonatal intensive care unit (NICU) for irritability, poor feeding, and tachypnea. On admission to the NICU, his examination revealed an irritable infant with tachypnea, mild retractions, and tachycardia. Cardiovascular examination revealed a hyperdynamic precordium, a loud second heart sound, a grade 3/6 holosystolic murmur best heard at the left lower parasternal border, with no thrill and no sternal heave. Breath sounds were equal bilaterally with no audible crackles. The liver was palpable 4 cm below the right and left costal margin and extending to the epigastrium, with a bruit heard over the liver on auscultation. There was no splenomegaly and no vascular malformations noted over the skin. In view of the presence of hepatomegaly, liver ultrasonography was performed, which showed a heterogeneous liver with multiple isoechoic and hyperechoic masses in both lobes of the liver. Color Doppler imaging showed internal and peripheral color flow, suggesting a possible vascular malformation. Magnetic resonance imaging (MRI) scan of the abdomen showed hepatomegaly with multiple areas of rounded masses with increased T2/STIR signal intensities and low TI/VIBE signal intensities. Following injection of contrast material, the lesions showed increased signal intensities. Mild tapering of the abdominal aorta was noted below the origin of the celiac axis. All these findings suggested multifocal IHH of the liver with a significant left to right shunting. Chest radiograph revealed a mildly enlarged cardiac silhouette with increased pulmonary vascularity without pulmonary infiltrations. A complete blood count showed mild anemia and thrombocytopenia with no evidence of microangiopathic hemolysis. Liver function tests showed mildly elevated liver enzymes. Laboratory evaluation of disseminated intravascular coagulation yielded negative results. Biochemical evaluation of pulmonary hypertension revealed markedly elevated (>5,000 pg/mL) B-natriuretic peptide (BNP). There was no evidence of prerenal azotemia (blood urea nitrogen: 10; creatinine: 0.49). Serum α-fetoprotein level was within normal limits for the neonatal period.

As PPHN was secondary to increased pulmonary blood flow from arteriovenous shunting at the level of IHH, the infant was managed with fluid restriction and diuretics. Target saturation was set at 95% to prevent worsening of pulmonary hypertension. However, the infant did not require oxygen to achieve the target saturation range. To enhance the involution of IHH, oral prednisolone (4 mg/kg/day, in 2 divided doses) and oral propranolol (0.6 mg/kg/day, in 3 divided doses) were started. The dose of propranolol was increased by 0.5 mg/kg/day, once in every 3 to 4 days to a maximum dose of 2 mg/kg/day. To monitor the improvement in PPHN, serial BNP (twice weekly) and serial echocardiograms (twice weekly) were performed. Over the next 3 weeks, as an evidence of response to medical management, serial BNP levels showed a significant reduction and was normal (<100 pg/mL) at the time of discharge. On serial echocardiograms, pulmonary arterial pressure showed a decreasing trend with normal pulmonary arterial pressure and no evidence of right ventricular hypertrophy or dilatation at the time of discharge. Postdischarge follow-up visits confirmed the continued response to treatment. Currently, the infant is on tapering doses of oral steroid and will remain on propranolol monotherapy for up to 1 year of age.
Discussion

Elevated pulmonary vascular resistance (PVR) is the key pathophysiological mechanism for PPHN in the immediate postnatal period. Systemic arteriovenous fistulas such as cerebral vein of Galen malformation, large cerebral arteriovenous malformations and hepatic arteriovenous malformations can lead to an obligatory pulmonary overcirculation and have been reported to manifest with PPHN in the immediate postnatal period. In the index case, the diffuse, large IHH acted as a conduit for systemic arteriovenous shunting, resulting in the obligatory increase in pulmonary blood flow during the early postnatal pulmonary vasorelaxation and after ductal constriction. Coupled with physiologically elevated PVR, the increase in pulmonary blood flow might have contributed for PPHN in the index case. Increased pulmonary blood flow also would delay the postnatal physiological drop in the PVR, which might be the other reason for the development of PPHN in the index case. Hence, any infants presenting with unexplained PPHN with evidence of hyperdynamic circulation in the absence of congenital heart disease, the differential diagnosis should include cranial and liver systemic arteriovenous fistulas. Appropriate imaging studies should be obtained. To our knowledge, this is the first case report reporting the association of IHH with PPHN.

Fetal pulmonary overcirculation because of ductal constriction (antenatal exposure to nonsteroidal anti-inflammatory medications) and experimental ductal ligation have shown to result in the vascular remodeling and idiopathic pulmonary hypertension. The consequent sustained increase in fetal pulmonary blood flow is the underlying pathophysiology for pulmonary vascular remodeling. However, with IHH, fetal pulmonary overcirculation is a rare possibility due to the parallel nature of fetal circulation and a markedly elevated fetal PVR. As PPHN resolved rapidly after the interventions that ameliorated increased pulmonary blood flow (diuretics and interventions to regress IHH), we speculate that fetal pulmonary vascular remodeling was not present in the index case.

IHH is a benign hepatic vascular tumor consisting of a network of capillary sized and endothelium-lined vessels, occurring more frequently in females. The International Society for the Study of Vascular Anomalies (ISSVA) classification categorizes IHH under vasoproliferative vascular tumor and names it as a type of infantile or hepatic hemangioma as it exhibits typical triphasic course (proliferative, plateau, and involution phase) just as in infantile hemangiomas. The newer ISSVA 2015 classification names it under benign vascular tumor category. Based on the presentation, IHH can be categorized as focal, multifocal, and diffuse types, with focal being the most common type. Most of the affected infants present by 6 months of age, with early onset symptoms indicating significant disease severity, as seen in the index case, where a large multifocal IHH contributed to significant hemodynamic consequences. The majority of untreated diffuse and multifocal IHH progresses to develop high-output congestive heart failure, which would have occurred in the index case if not recognized and treated early. It has been reported that approximately 50 to 60% of all IHHs have hemodynamically significant shunt to cause left-sided volume overload leading to high-output congestive heart failure. Although focal IHHs are benign in nature with spontaneous regression, diffuse and multifocal
types manifest with more severe clinical progression to severe cardiac failure, Kasabach–Merritt syndrome with consumptive coagulopathy, intra-abdominal hemorrhage, and liver failure resulting in high mortality.22

Even though liver ultrasonography is the most often performed initial diagnostic test for radiologic diagnosis of IHH, MRI is the modality of choice for radiologic confirmation of IHH. Pre- and postcontrast T1-weighted images and T2-weighted axial images are the most useful MRI sequences for diagnosing of IHH (Fig. 2).10 An ultrafast, rapid sequence T2-weighted MRI image sequence has also been described for the follow-up imaging studies to monitor the growth of IHH.23

Prompt and effective treatment was important in the index case due to the multifocal nature of the lesion and the clinical presentation. Although currently there are controversies in the management options for IHH, a prolonged oral steroid19,20 administration is the mainstay of treatment. However, approximately 25% of infants with IHH treated with steroid are completely unresponsive to treatment.19 Moreover, propranolol, which is a proven treatment strategy for rapid improvement in the clinical symptoms and to prevent complications associated with systemic arteriovenous shunting. To the best of our knowledge, a similar combination treatment strategy for the management of IHH has been reported previously by Bosemani et al.23

In summary, we have reported a case of early symptomatic IHH in a term newborn infant presenting with hyperkinetic PPHN, which was managed successfully with fluid restriction and diuretic use along with systemic pharmacological therapy directed toward enhancing involution of IHH. Our experience emphasizes the importance of a high index of suspicion and prompt evaluation for IHH and related systemic arteriovenous shunts among infants with unexplained pulmonary hypertension with evidence of hyperdynamic circulation.

References
12 Gao Y, Raj JL. Regulation of the pulmonary circulation in the fetus and newborn. Physiol Rev 2010;90(4):1291–1335